Liver Transplantation After Immune Checkpoint Inhibition in Hepatocellular Carcinoma—Data From the Multinational LITCHI Registry
Authors:
- Ulrike BauerUBUlrike Bauer
- Maria R. TroppmairMTMaria R. Troppmair
- Najib Ben KhaledNKNajib Ben Khaled
- Julia M. GrottenthalerJGJulia M. Grottenthaler
- Friedrich FoersterFFFriedrich Foerster
- Sena BlümelSBSena Blümel
- Sophia HeinrichSHSophia Heinrich
- Friedrich SinnerFSFriedrich Sinner
- Matthias PinterMPMatthias Pinter
- Magdalena HahnMHMagdalena Hahn
- Florian van BömmelFBFlorian van Bömmel
- Bernhard ScheinerBSBernhard Scheiner
Open Access
- 19 May 2026
- journal article
- research article
- Published by Wiley in Liver International
- Vol. 46 (6) , e70692
Abstract
Evidence supporting the safety and efficacy of immune checkpoint inhibitors (ICI) before liver transplantation (LTx) in hepatocellular carcinoma (HCC) is increasing, but risks of graft rejection and tumour recurrence remain major concerns. We evaluated post‐transplant outcomes across 10 European centres using data from the multinational LITCHI ( Li ver t ransplantation after i mmune c heckpoint i nhibition) registry. Clinical and tumour characteristics, ICI regimens and post‐transplant immunosuppression were assessed, and overall and rejection‐free survival were estimated using the log‐rank test. Among 18 patients who underwent LTx following ICI, 15 were treated with atezolizumab plus bevacizumab. One‐year survival was 77% (95% CI 67.3–87.8) and four rejection episodes occurred, with one fatal case after a 13‐day wash‐out and three non‐fatal episodes, each responsive to escalation of immunosuppression. Overall, however, no intensified immunosuppression was required in our cohort. Despite tumour burden beyond Milan criteria in most patients before ICI initiation, HCC recurrence occurred in only one patient.Keywords
Funding Information
- Roche
This publication has 16 references indexed in Scilit:
- Determining safe washout period for immune checkpoint inhibitors prior to liver transplantation: An international retrospective cohort studyHepatology, 2025
- Neoadjuvant atezolizumab plus bevacizumab prior liver transplantation for hepatocellular carcinomaJHEP Reports, 2024
- Intention-to-treat outcomes of patients with hepatocellular carcinoma receiving immunotherapy before liver transplant: The multicenter VITALITY studyJournal of Hepatology, 2024
- Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: A systematic review and individual patient data meta-analysisJournal of Hepatology, 2024
- Immunotherapy for hepatocellular carcinoma: The next evolution in expanding access to liver transplantationJournal of Hepatology, 2024
- Hepatocellular carcinoma downstaging for liver transplantation in the era of systemic combined therapy with anti‐VEGF/TKI and immunotherapyHepatology, 2022
- Rescue liver re-transplantation after graft loss due to severe rejection in the setting of pre-transplant nivolumab therapyClinical Journal of Gastroenterology, 2021
- Immunotherapy as a Downstaging Therapy for Liver TransplantationHepatology, 2020
- Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are checkpoint inhibitors safe for the pretransplant patient?American Journal of Transplantation, 2020
- Acute and Chronic Rejection After Liver Transplantation: What A Clinician Needs to KnowJournal of Clinical and Experimental Hepatology, 2017